Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 503

1.

HCV Cure Rates are Reduced in Patients with Active but not Inactive Hepatocellular Carcinoma- A Practice Implication.

Ogawa E, Toyoda H, Iio E, Jun DW, Huang CF, Enomoto M, Hsu YC, Haga H, Iwane S, Wong G, Lee DH, Tada T, Liu CH, Chuang WL, Hayashi J, Cheung R, Yasuda S, Tseng CH, Takahashi H, Tran S, Yeo YH, Henry L, Barnett SD, Nomura H, Nakamuta M, Dai CY, Huang JF, Yang HI, Lee MH, Jung Jun M, Kao JH, Eguchi Y, Ueno Y, Tamori A, Furusyo N, Yu ML, Tanaka Y, Nguyen MH; REAL-C Investigators, Ahn SB, Azuma K, Dohmen K, Yoon Jeong J, Jung JH, Kajiwara E, Kato M, Kawano A, Koyanagi T, Ooho A, Park SH, Satoh T, Shimoda S, Song DS, Takahashi K, Yeh ML, Yoon EL.

Clin Infect Dis. 2019 Nov 28. pii: ciz1160. doi: 10.1093/cid/ciz1160. [Epub ahead of print]

PMID:
31777940
2.

Early Fibrosis but Late Tumor Stage and Worse Outcomes in Hepatocellular Carcinoma Patients Without Hepatitis B or Hepatitis C.

Hsu PY, Hsu CT, Yeh ML, Huang CF, Huang CI, Liang PC, Lin YH, Hsieh MY, Wei YJ, Hsieh MH, Dai CY, Lin ZY, Chen SC, Huang JF, Yu ML, Chuang WL.

Dig Dis Sci. 2019 Nov 13. doi: 10.1007/s10620-019-05938-3. [Epub ahead of print]

PMID:
31722058
3.

Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: The EXPEDITION-8 trial.

Brown RS Jr, Buti M, Rodrigues L, Chulanov V, Chuang WL, Aguilar H, Horváth G, Zuckerman E, Carrion BR, Rodriguez-Perez F, Urbánek P, Abergel A, Cohen E, Lovell SS, Schnell G, Lin CW, Zha J, Wang S, Trinh R, Mensa FJ, Burroughs M, Felizarta F.

J Hepatol. 2019 Nov 2. pii: S0168-8278(19)30647-6. doi: 10.1016/j.jhep.2019.10.020. [Epub ahead of print]

4.

Pharmacokinetics and pharmacodynamics of pegylated interferon for the treatment of hepatitis B.

Yeh ML, Huang JF, Dai CY, Yu ML, Chuang WL.

Expert Opin Drug Metab Toxicol. 2019 Oct;15(10):779-785. doi: 10.1080/17425255.2019.1678584. Epub 2019 Oct 12. Review.

PMID:
31593639
5.

APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation.

Kanda T, Lau GKK, Wei L, Moriyama M, Yu ML, Chuang WL, Ibrahim A, Lesmana CRA, Sollano J, Kumar M, Jindal A, Sharma BC, Hamid SS, Kadir Dokmeci A, Mamun-Al-Mahtab, McCaughan GW, Wasim J, Crawford DHG, Kao JH, Ooka Y, Yokosuka O, Sarin SK, Omata M.

Hepatol Int. 2019 Nov;13(6):649-661. doi: 10.1007/s12072-019-09988-7. Epub 2019 Sep 20.

6.

Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C Consortium.

Huang CF, Iio E, Jun DW, Ogawa E, Toyoda H, Hsu YC, Haga H, Iwane S, Enomoto M, Lee DH, Wong G, Liu CH, Tada T, Chuang WL, Cheung R, Hayashi J, Tseng CH, Yasuda S, Tran S, Kam L, Henry L, Jeong JY, Nomura H, Park SH, Nakamuta M, Huang JF, Tai CM, Lo GH, Lee MH, Yang HI, Kao JH, Tamori A, Eguchi Y, Ueno Y, Furusyo N, Tanaka Y, Yu ML, Nguyen MH; REAL-C Investigators.

Hepatol Int. 2019 Sep;13(5):587-598. doi: 10.1007/s12072-019-09974-z. Epub 2019 Aug 28.

PMID:
31463665
7.

Improvement of hyperuricemia in chronic hepatitis C patients receiving directly acting antiviral agents.

Jang TY, Huang CI, Yeh ML, Liang PC, Tsai PC, Lin YH, Hsieh MY, Hou NJ, Lin ZY, Chen SC, Huang JF, Dai CY, Huang CF, Chuang WL, Yu ML.

J Gastroenterol Hepatol. 2019 Aug 14. doi: 10.1111/jgh.14835. [Epub ahead of print]

PMID:
31414504
8.

Wisteria floribunda agglutinin-positive Mac-2-binding protein in the prediction of disease severity in chronic hepatitis B patients.

Yeh ML, Huang CF, Huang CI, Dai CY, Lin IH, Liang PC, Hsieh MH, Lin ZY, Chen SC, Huang JF, Chen JJ, Yu ML, Chuang WL.

PLoS One. 2019 Aug 8;14(8):e0220663. doi: 10.1371/journal.pone.0220663. eCollection 2019.

9.

Ribavirin facilitates early viral kinetics in chronic hepatitis C patients receiving daclatasvir/asunaprevir.

Huang CF, Yeh ML, Huang CI, Liang PC, Lin YH, Hsieh MY, Chen KY, Ko YM, Lin ZY, Chen SC, Huang JF, Dai CY, Chuang WL, Yu ML.

J Gastroenterol Hepatol. 2019 Aug 1. doi: 10.1111/jgh.14815. [Epub ahead of print]

PMID:
31373037
10.

Higher NAFLD fibrosis score is associated with impaired eGFR.

Hsieh MH, Wu KT, Chen YY, Yang JF, Lin WY, Chang NC, Lin CY, Huang CK, Wang CL, Chuang HY, Lin SC, Hsu YK, Tsai YS, Chuang WL, Yu ML, Dai CY.

J Formos Med Assoc. 2019 Jul 25. pii: S0929-6646(19)30160-3. doi: 10.1016/j.jfma.2019.07.007. [Epub ahead of print]

11.

Large-scale viral genome analysis identifies novel clinical associations between hepatitis B virus and chronically infected patients.

Podlaha O, Gane E, Brunetto M, Fung S, Chuang WL, Pan CQ, Jiang Z, Liu Y, Bhardwaj N, Mukherjee P, Flaherty J, Gaggar A, Subramanian M, Izumi N, Shalimar, Lim YS, Marcellin P, Buti M, Chan HLY, Agarwal K.

Sci Rep. 2019 Jul 19;9(1):10529. doi: 10.1038/s41598-019-46609-7.

12.

Blockade of STAT3 Signaling Contributes to Anticancer Effect of 5-Acetyloxy-6,7,8,4'-Tetra-Methoxyflavone, a Tangeretin Derivative, on Human Glioblastoma Multiforme Cells.

Cheng YP, Li S, Chuang WL, Li CH, Chen GJ, Chang CC, Or CR, Lin PY, Chang CC.

Int J Mol Sci. 2019 Jul 9;20(13). pii: E3366. doi: 10.3390/ijms20133366.

13.

The prognostic factors between different viral etiologies among advanced hepatocellular carcinoma patients receiving sorafenib treatment.

Yeh ML, Huang CF, Huang CI, Hsieh MY, Hou NJ, Lin IH, Liang PC, Tsai YS, Hsieh MH, Lin ZY, Chen SC, Dai CY, Huang JF, Yu ML, Chuang WL.

Kaohsiung J Med Sci. 2019 Oct;35(10):624-632. doi: 10.1002/kjm2.12105. Epub 2019 Jun 28.

14.

Axl and autophagy LC3 expression in tumors is strongly associated with clinical prognosis of hepatocellular carcinoma patients after curative resection.

Hsu CC, Hsieh PM, Chen YS, Lo GH, Lin HY, Dai CY, Huang JF, Chuang WL, Chen YL, Yu ML, Lin CW.

Cancer Med. 2019 Jul;8(7):3453-3463. doi: 10.1002/cam4.2229. Epub 2019 May 16.

15.

Integrated care for methadone maintenance patients with hepatitis C virus infection.

Tai CM, Yen YC, Bair MJ, Tseng CH, Chang TT, Huang CF, Yeh ML, Dai CY, Chuang WL, Yu ML, Huang JF.

Kaohsiung J Med Sci. 2019 Aug;35(8):501-507. doi: 10.1002/kjm2.12086. Epub 2019 May 14.

16.

Equal treatment efficacy of direct-acting antivirals in patients with chronic hepatitis C and hepatocellular carcinoma? A prospective cohort study.

Huang CF, Yeh ML, Huang CI, Liang PC, Lin YH, Hsieh MY, Wei YJ, Lin ZY, Chen SC, Huang JF, Dai CY, Chuang WL, Yu ML.

BMJ Open. 2019 May 5;9(5):e026703. doi: 10.1136/bmjopen-2018-026703.

17.

Mac-2 Binding Protein Glycosylation Isomer as a Hepatocellular Carcinoma Marker in Patients With Chronic Hepatitis B or C Infection.

Jun T, Hsu YC, Ogawa S, Huang YT, Yeh ML, Tseng CH, Huang CF, Tai CM, Dai CY, Huang JF, Chuang WL, Yu ML, Tanaka Y, Nguyen MH.

Hepatol Commun. 2019 Feb 8;3(4):493-503. doi: 10.1002/hep4.1321. eCollection 2019 Apr.

18.

Clinical evaluation of IntelliPlexTM HCV genotyping kit for hepatitis C virus genotyping.

Kao JH, Lin CY, Chuang WL, Cheng YY, Hu JY, Liang WK, Friebe P, Palmer S, Huang CS.

Diagn Microbiol Infect Dis. 2019 Aug;94(4):344-348. doi: 10.1016/j.diagmicrobio.2019.02.020. Epub 2019 Mar 12.

PMID:
30975461
19.

An Open-Label, Randomized, Active-Controlled Trial of 8 Versus 12 Weeks of Elbasvir/Grazoprevir for Treatment-Naive Patients With Chronic Hepatitis C Genotype 1b Infection and Mild Fibrosis (EGALITE Study): Impact of Baseline Viral Loads and NS5A Resistance-Associated Substitutions.

Huang CF, Hung CH, Cheng PN, Bair MJ, Huang YH, Kao JH, Hsu SJ, Lee PL, Chen JJ, Chien RN, Peng CY, Lin CY, Hsieh TY, Cheng CH, Dai CY, Huang JF, Chuang WL, Yu ML.

J Infect Dis. 2019 Jul 19;220(4):557-566. doi: 10.1093/infdis/jiz154.

PMID:
30957170
20.

Risk stratification of non-alcoholic fatty liver disease across body mass index in a community basis.

Huang JF, Tsai PC, Yeh ML, Huang CF, Huang CI, Hsieh MH, Dai CY, Yang JF, Chen SC, Yu ML, Chuang WL, Chang WY.

J Formos Med Assoc. 2019 Apr 2. pii: S0929-6646(19)30005-1. doi: 10.1016/j.jfma.2019.03.014. [Epub ahead of print]

Supplemental Content

Loading ...
Support Center